YU75600A - Upotreba polipeptida faktora transkripcije e - Google Patents
Upotreba polipeptida faktora transkripcije eInfo
- Publication number
- YU75600A YU75600A YU75600A YU75600A YU75600A YU 75600 A YU75600 A YU 75600A YU 75600 A YU75600 A YU 75600A YU 75600 A YU75600 A YU 75600A YU 75600 A YU75600 A YU 75600A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- transcription
- nucleic acid
- acid molecules
- treatment
- sequence
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 abstract 3
- 102000040945 Transcription factor Human genes 0.000 abstract 2
- 108091023040 Transcription factor Proteins 0.000 abstract 2
- 206010052428 Wound Diseases 0.000 abstract 2
- 208000027418 Wounds and injury Diseases 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 241000282412 Homo Species 0.000 abstract 1
- 241000282414 Homo sapiens Species 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 101100444898 Mus musculus Egr1 gene Proteins 0.000 abstract 1
- 101100445499 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) erg-1 gene Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000035897 transcription Effects 0.000 abstract 1
- 238000013518 transcription Methods 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Ovaj pronalazak se odnosi na upotrebu polipeptida sa faktorom transkripcije Egr-1 ili njegovog biološki aktivnog fragmenta i na molekule nukleinskih kiselina koji kodiraju takve peptide, za proizvodnju medikamenta za tretiranje rana kod sisara, uključujući humano biće. Pored toga, odnosi se na sekvenciju koja sadrži značajne regione uključene u transkripciju faktora transkripcije Erg-1 kod humanih bića i na njenu regulaciju. Ova sekvencija se može koristiti za dizajniranje odgovarajućih molekula i vektora nukleinskih kiselina koji se mogu koristiti u tretmanu rana, kao i u drugim tretmanima.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9811836.7A GB9811836D0 (en) | 1998-06-02 | 1998-06-02 | Gene therapy method |
| GBGB9815035.2A GB9815035D0 (en) | 1998-07-11 | 1998-07-11 | Gene therapy method |
| GBGB9819846.8A GB9819846D0 (en) | 1998-09-12 | 1998-09-12 | Gene therapy method |
| GBGB9828578.6A GB9828578D0 (en) | 1998-12-23 | 1998-12-23 | Regulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU75600A true YU75600A (sh) | 2004-03-12 |
Family
ID=27451790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU75600A YU75600A (sh) | 1998-06-02 | 1999-06-02 | Upotreba polipeptida faktora transkripcije e |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6689758B1 (sh) |
| EP (2) | EP1083934B1 (sh) |
| JP (1) | JP2002516676A (sh) |
| KR (1) | KR20010043968A (sh) |
| CN (1) | CN1311822A (sh) |
| AP (1) | AP2000001999A0 (sh) |
| AT (1) | ATE246518T1 (sh) |
| AU (1) | AU770497B2 (sh) |
| BR (1) | BR9910877A (sh) |
| CA (1) | CA2334171A1 (sh) |
| DE (1) | DE69910202T2 (sh) |
| DK (1) | DK1083934T3 (sh) |
| EA (1) | EA200001124A1 (sh) |
| EE (1) | EE200000790A (sh) |
| ES (1) | ES2205830T3 (sh) |
| HK (1) | HK1034465A1 (sh) |
| HR (1) | HRP20000832A2 (sh) |
| HU (1) | HUP0103252A3 (sh) |
| ID (1) | ID27483A (sh) |
| IL (1) | IL139936A0 (sh) |
| IS (1) | IS5742A (sh) |
| NO (1) | NO20006047L (sh) |
| NZ (1) | NZ508505A (sh) |
| PL (1) | PL345207A1 (sh) |
| PT (1) | PT1083934E (sh) |
| SK (1) | SK18322000A3 (sh) |
| TR (2) | TR200100348T2 (sh) |
| WO (1) | WO1999062561A2 (sh) |
| YU (1) | YU75600A (sh) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9928430D0 (en) * | 1999-12-01 | 2000-01-26 | Glaxo Group Ltd | Screening |
| AU2003202489A1 (en) * | 2002-01-10 | 2003-07-30 | Takeda Chemical Industries, Ltd. | Screening method |
| WO2004060476A2 (en) * | 2002-12-31 | 2004-07-22 | The Johns Hopkins University | Wound healing method and kits |
| CA2537184A1 (en) * | 2003-08-29 | 2005-03-10 | Anges Mg, Inc. | Gene therapy for skin disorders using needleless syringes |
| DE10342071B4 (de) * | 2003-09-10 | 2006-01-19 | Fleischmann, Wilhelm, Dr.med. | Vorrichtung und Verfahren zur Applikation von Wïrkstoffen an eine Wundoberfläche |
| KR100647490B1 (ko) | 2004-10-04 | 2006-11-23 | 사회복지법인 삼성생명공익재단 | 저산소 조건 및 다른 스트레스에 특이적으로 반응할 수있는 키메라 인핸서 요소를 포함하는 벡터, 상기 벡터를포함하는 약제학적 조성물 및 상기 조성물을 이용하는 방법 |
| WO2008141308A2 (en) | 2007-05-11 | 2008-11-20 | Adynxx, Inc. | Gene expression and pain |
| FR2920158B1 (fr) * | 2007-08-24 | 2010-03-12 | Centre Nat Rech Scient | Production de plasmides et expression de proteines recombinantes dans des cellules cultivees sans antibiotiques |
| FR2924128A1 (fr) * | 2007-11-26 | 2009-05-29 | Galderma Res & Dev | Modulateurs de egr1 dans le traitement de l'alopecie |
| BR112012000865A2 (pt) | 2009-07-17 | 2019-09-24 | T Tabor Aaron | "composição e método para a modificação genética cosmética de células substancialmente intactas" |
| CN102552938A (zh) * | 2012-03-22 | 2012-07-11 | 南京大学 | Egr-1拮抗剂在制备治疗Ⅱ型糖尿病的药物中的用途 |
| CN104487096B (zh) | 2012-05-10 | 2020-09-15 | 埃迪恩克斯股份有限公司 | 用于活性成分递送的配制物 |
| ES2750689T3 (es) | 2014-08-15 | 2020-03-26 | Adynxx Inc | Señuelos oligonucleotídicos para el tratamiento del dolor |
| KR101721228B1 (ko) * | 2015-04-03 | 2017-03-30 | 사회복지법인 삼성생명공익재단 | 지방유래 줄기세포의 배양액을 유효성분으로 포함하는 발모촉진용 조성물 |
| CN104857529A (zh) * | 2015-05-20 | 2015-08-26 | 山西大学 | Egr-1基因在制备抗膀胱癌药物中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5763209A (en) | 1988-09-26 | 1998-06-09 | Arch Development Corporation | Methods and materials relating to the functional domains of DNA binding proteins |
| US5206152A (en) * | 1988-04-08 | 1993-04-27 | Arch Development Corporation | Cloning and expression of early growth regulatory protein genes |
| AUPN855496A0 (en) | 1996-03-07 | 1996-04-04 | Unisearch Limited | Prevention of proliferation of vascular cells |
-
1999
- 1999-06-02 EE EEP200000790A patent/EE200000790A/xx unknown
- 1999-06-02 DK DK99925174T patent/DK1083934T3/da active
- 1999-06-02 CN CN99809287A patent/CN1311822A/zh active Pending
- 1999-06-02 US US09/701,749 patent/US6689758B1/en not_active Expired - Fee Related
- 1999-06-02 SK SK1832-2000A patent/SK18322000A3/sk unknown
- 1999-06-02 BR BR9910877-1A patent/BR9910877A/pt not_active IP Right Cessation
- 1999-06-02 AP APAP/P/2000/001999A patent/AP2000001999A0/en unknown
- 1999-06-02 HU HU0103252A patent/HUP0103252A3/hu unknown
- 1999-06-02 WO PCT/GB1999/001722 patent/WO1999062561A2/en not_active Application Discontinuation
- 1999-06-02 YU YU75600A patent/YU75600A/sh unknown
- 1999-06-02 EP EP99925174A patent/EP1083934B1/en not_active Expired - Lifetime
- 1999-06-02 AT AT99925174T patent/ATE246518T1/de not_active IP Right Cessation
- 1999-06-02 EP EP02020179A patent/EP1281763A3/en not_active Withdrawn
- 1999-06-02 TR TR2001/00348T patent/TR200100348T2/xx unknown
- 1999-06-02 CA CA002334171A patent/CA2334171A1/en not_active Abandoned
- 1999-06-02 JP JP2000551815A patent/JP2002516676A/ja active Pending
- 1999-06-02 AU AU41560/99A patent/AU770497B2/en not_active Expired - Fee Related
- 1999-06-02 DE DE69910202T patent/DE69910202T2/de not_active Expired - Fee Related
- 1999-06-02 EA EA200001124A patent/EA200001124A1/ru unknown
- 1999-06-02 IL IL13993699A patent/IL139936A0/xx unknown
- 1999-06-02 NZ NZ508505A patent/NZ508505A/xx unknown
- 1999-06-02 ID IDW20002711A patent/ID27483A/id unknown
- 1999-06-02 PT PT99925174T patent/PT1083934E/pt unknown
- 1999-06-02 ES ES99925174T patent/ES2205830T3/es not_active Expired - Lifetime
- 1999-06-02 TR TR2001/02985T patent/TR200102985T2/xx unknown
- 1999-06-02 PL PL99345207A patent/PL345207A1/xx not_active Application Discontinuation
- 1999-06-02 KR KR1020007013584A patent/KR20010043968A/ko not_active Application Discontinuation
-
2000
- 2000-11-28 IS IS5742A patent/IS5742A/is unknown
- 2000-11-29 NO NO20006047A patent/NO20006047L/no not_active Application Discontinuation
- 2000-12-01 HR HR20000832A patent/HRP20000832A2/hr not_active Application Discontinuation
-
2001
- 2001-07-24 HK HK01105197A patent/HK1034465A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU75600A (sh) | Upotreba polipeptida faktora transkripcije e | |
| BR0109494A (pt) | Produção de fatores recombinantes de coagulação do sangue em linhas celulares humanas | |
| ATE186219T1 (de) | Kombination von antihormonale und bindende moleküle zur krebsbehandlung | |
| DE50112802D1 (de) | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen | |
| DE69333550D1 (de) | TNF-alpha RIBOZYME UND ABBAU-RESISTENTE mRNA DERIVATIVE GEBUNDEN AN TNF-alpha Ribozyme | |
| AR002742A1 (es) | Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn | |
| ATE326981T1 (de) | Isolierte peptide die aminosäuresequenzen von ny- eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen | |
| ATE443076T1 (de) | Von protease typ ii spaltbares peptid | |
| DE60039677D1 (de) | Akt-3 nukleinsäure, polypeptide und deren verwendung | |
| DE60034879T8 (de) | Lantibiotikum | |
| ATE302210T1 (de) | Histogranin peptide und deren analgetische verwendung | |
| ATE356145T1 (de) | Polypeptide zur regenerierung des nervensystems | |
| DK1012285T3 (da) | Hidtil ukendte beta-defensiner | |
| ATE490324T1 (de) | Nukleinsäuren kodierend für polypeptide mit chips aktivität | |
| ATE552271T1 (de) | Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon | |
| PT804182E (pt) | Utilizacao de gabapentina para o tratamento da ansiedade e do panico | |
| DE69330348D1 (de) | Verwendung von Peptiden welche eine Immunantwort bewirken zur Herstellung von Medikamenten zur Induzierung der Immunsuppression. | |
| AR006641A1 (es) | Molecula de acido nucleico que codifica un peptido inmunoreactivo, un vector de expresion mamifero, una particula viral, una celula de mamifero, unmetodo para producir un peptido inmunoreactivo, un metodo para modular la respuesta inmune, el uso de la molecula de acido nucleico en terapia y una | |
| DK0811068T3 (da) | Humane DNase I varianter | |
| EA200100028A1 (ru) | Фармацевтические применения nab1 и nab2 | |
| DE59813829D1 (de) | Verwendung von histonen zur herstellung von arzneimitteln | |
| Vetvicka et al. | E4 2: 30 Biological activity of coelomic fluid of Eisenia foetida | |
| ATE223227T1 (de) | Verwendung von lbp zur sepsistherapie | |
| Critical Care Society of South Africa Working Group | Severe sepsis and the role of novel therapeutic agents. Position statement of the Critical Care Society of South Africa on severe sepsis and the role of novel therapeutic agents such as drotrecogin alfa (activated) | |
| WO2003035692A3 (en) | Modified peptides and their uses |